Entrar/Registro  
INICIO ENGLISH
 
Boletín Médico del Hospital Infantil de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Boletín Médico del Hospital Infantil de México >Año 2009, No. 1


Río-Navarro BE, Hidalgo-Castro EM, Sienra-Monge JJL
Asma
Bol Med Hosp Infant Mex 2009; 66 (1)

Idioma: Español
Referencias bibliográficas: 98
Paginas: 3-33
Archivo PDF: 905.71 Kb.


Texto completo




RESUMEN

El asma es una enfermedad inflamatoria crónica de las vías aéreas en la cual muchas células y productos celulares juegan un papel importante. La inflamación crónica produce un incremento en la reactividad de la vía aérea y episodios recurrentes de sibilancias, dificultad respiratoria, tiraje intercostal, tos y opresión torácica, especialmente en la noche y en la mañana. Estos episodios se asocian con obstrucción del flujo aéreo, reversible espontáneamente o con tratamiento. La inflamación también causa un aumento en la respuesta bronquial a una gran variedad de estímulos. Es la enfermedad crónica más común en la infancia, los estudios epidemiológicos en América Latina han revelado diferencias en prevalencia del asma con cifras de 5.7 a 16.5% en la población pediátrica. En los últimos años se han realizado estudios en la Ciudad de México aplicando la metodología del ISAAC, determinando que la prevalencia es de 8 a 12%. Varios factores de riesgo se asocian con el desarrollo de esta enfermedad, a continuación se exponen éstos, así como la fisiopatología de la enfermedad, manifestaciones clínicas, estrategias de diagnóstico y opciones terapéuticas.


Palabras clave: Asma, hiperreactividad bronquial, enfermedad crónica, niños.


REFERENCIAS

  1. Archivo del Hospital Infantil de México Federico Gómez. Datos de 2007.

  2. The Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2006.

  3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, NHLBI/WHO Workshop report. Bethesda: National Institutes of Health; National Heart, Lung and Blood Institute; 2002.

  4. Jeffery P. Inflammation and remodeling in the adult and child with asthma. Pediatr Pulmonol. 2001; 32 S21: 3-16.

  5. Rasmussen F, Taylor R, Flannery E. Risk factors for airway remodeling in asthma manifested by a low post bronchodilator FEV1/vital capacity ratio. Am J Respir Crit Care Med. 2002; 165: 1480-8.

  6. NAEPP 2007.

  7. Liu A, Szefler S. Advances in childhood asthma: Hygiene hypothesis, natural history and management. J Allergy Clin Immunol. 2003; 111: 787-92.

  8. The Global Initiative for Asthma. Global strategy for asthma management and prevention. Definition and Overview; 2006. p. 2-13.

  9. Braman SS. The global burden of asthma. Chest. 2006; 30 Suppl 1: 45-125.

  10. Mallol, et al. Prevalence of asthma symptoms in Latin America: The International Study of Asthma and Allergies in Childhood. Pediatr Pulmonol. 2000; 30: 263-4.

  11. Baeza BMA, Graham ZLF. Prevalencia del asma: encuesta en una población escolar de Villahermosa, Tabasco, México. Alergia. 1992; 39: 32-6.

  12. González-Gómez JG, Barrera-Gómez LE, Arévalo-Orozco MA. Prevalencia del asma bronquial en población escolar en la ciudad de Guadalajara, Jalisco, México. Alergia. 1992; 32: 3-7.

  13. Canseco-González C, Leal-de Hernández L, Mora-Zepeda H, Galindo-de Jaime G. Epidemiología de las enfermedades alérgicas en el área metropolitana de Monterrey. Alergia. 1991; 38: 95-101.

  14. Baeza-Bacab MA, Albertos-Alpuche NE. Prevalencia del asma en niños escolares de Mérida, Yucatán. Rev Panam Salud Publica. 1997; 2: 299-302.

  15. Tatto-Cano MI, Sanín-Aguirre LH, González V, Ruiz-Velasco S, Romieu l. Prevalencia de asma, rinitis y eczema en escolares de la ciudad de Cuernavaca, Morelos. Salud Publica Mex. 1997; 39: 497-506.

  16. Barraza-Villarreal V, et al. Prevalencia de asma y otras enfermedades alérgicas en niños escolares de Ciudad Juárez, Chihuahua. Salud Publica Mex. 2001; 43: 433-43.

  17. Mendoza A, Romero J, Peña H, Vargas M. Prevalencia de asma en los niños escolares de la ciudad mexicana de Hermosillo. Gac Med Mex. 2001; 137: 397-401.

  18. Del Río BE, del Río JM, Berber A, Rosas MA, Sienra-Monge JJL. Asthma prevalence in children living in north Mexico City and comparison with other Latin America cities and world regions. Allergy Asthma Proc. 2006; 27: 334-40.

  19. Del Río BE, del Río JM, Rosas MA, Sienra MJJL. Prevalencia de asma al norte de la ciudad de México. México: Archivos del Hospital Infantil de México, Tesis; 2004.

  20. Del Río-Navarro B, et al. Prevalence of asthma in nine cities of Mexico in the ISAAC survey. Allergy. 2007; 62: S425-6.

  21. Neffen H, Baena-Cagnani C. Asthma mortality in Latin America. ACI International. 1999; 11: 171-5.

  22. Lemanske RF Jr, Busse WW. Asthma. J Allergy Clin Immunol. 2003; 111: S502-S19.

  23. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med. 2001; 344: 350-62.

  24. Sengler C, Lau S, Whan U, Nickel R. Interactions between genes and environmental factors in asthma and atopy: New developments. Respir Res. 2002; 3: 1-15.

  25. Warnes JJ. Prenatal sensitization in human. Pediatr Allergy Immunol. 2000; 13: S6-8.

  26. Walley AJ, Bhattacharyya S, Leaves N. Linkage and allelic association of chromosome 5 microsatellites markers with atopic asthma phenotypes in general population sample. Am J Resp Crit Care Med. 1997; 155: A 257.

  27. Blanco QC. Genética de la alergia. Genes reguladores de la respuesta alérgica. Alergol Inmunol Clin. 2000; 15: 40-62.

  28. Heinzman A, Deichmann. Genes for atopy and asthma. Curr Opin Allergy Clin Immunol. 2001; 1: 387-92.

  29. Shore SA, Fredberg JJ. Obesity, smooth muscle, and airway hyperresponsiveness. J Allergy Clin Immunol. 2005; 115: 925-7.

  30. Huang SL, Shiao G, Chou P. Association between body mass index and allergy in teenage girls in Taiwan. Clin Exp Allergy. 1999; 29: 323-9.

  31. Ibañez SL. Evolution of childhood asthma. Alergol Immunol Clin. 2000; 15: 53-8.

  32. Rowe J, Macaubas C, Monger T, Holt BJ, Harvey J, Poolman JT, et al. Heterogeneity in diphtheria-tetanus-acellular vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic Th1 function. J Infect Dis. 2001; 184: 80-8.

  33. Grüber CC, Meinlschmid GT, Bergmann R, Wahn U, Stark K. Is early BCG vaccination associated with less atopic disease? An epidemiologic study in German preschool children with different ethnic backgrounds. Pediatr Allergy Immunol. 2002; 13: 177-81.

  34. Hopkin JM. The rise of atopy and links to infection. Allergy. 2002; 57: S5-9.

  35. Sirgas N, Guastafsson PM, Jarnason B, Lundberg F, Schmidth S, et al. Severe respiratory syncitial virus broncholitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005; 171: 137-41.

  36. Johnston NW, Johnston SL, Duncan JM, Greene JM. The September epidemic asthma exacerbation in children: A search for etiology. J Allergy Clin Immunol. 2005; 115: 132-8.

  37. Herz U, Lacy P, Renz H, Erb K. The influences of infections on the development and severity of allergic disorders. Current Opin Allergy Clin Immunol. 2000; 12: 632-4.

  38. Hao M, Comier M, Wang M, Lee JJ, Nel A. Diesel exhaust particles exert acute effects on airway inflammation and function in murine allergen provocation models. J Allergy Clin Immunol. 2003; 112: 905-14.

  39. Devouassoux G, Saxon A, Metcalfe DD, Prussin C, Colomb MG, Brambilla C, et al. Chemical constituents of diesel exhaust particles induces IL-4 production and histamine release by human basophils. J Allergy Clin Immunol. 2002; 109: 847-53.

  40. Romieu I, Sienra J, Ramírez M, Moreno H, Reyes N, del Río B, et al. Genetic polymorphism of GSTM1 and antioxidant supplementation influence lung function in relation to ozone exposure in asthmatic children in Mexico City. Thorax. 2004; 59: 8-10.

  41. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002; 57: 226-30.

  42. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003; 168: 1308-11.

  43. Dezateux C, Stocks J, Dundas I, Fletcher ME. Impaired airway function and wheezing in infancy: the influence of maternal smoking and a genetic predisposition to asthma. Am J Respir Crit Care Med. 1999; 159: 403-10.

  44. Environmental tobacco smoke: A hazard to children. American Academy of Pediatrics Committee on Environmental Health. Pediatrics. 1997; 99: 639-42.

  45. Wahn U, Lau S, Bergmann R, Kulig M, Forster J, Bergmann K, et al. Indoor allergen exposure is a risk factor for sensitization during the first three years of life. J Allergy Clin Immunol. 1997; 99: 763-9.

  46. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med. 1990; 323: 502-7.

  47. Pearlman DS. Pathophysiology of the inflammatory response. J Allergy Clin Immunol. 1999; 104: S132-7.

  48. Lemanske RF. Inflammatory events in asthma: An expanding equation. J Allergy Clin Immunol. 2000; 105: S633-6.

  49. Prussin C, Metcalfe D. IgE, mast cell, basophils, and eosinophils. J Allergy Clin Immunol. 2003; 111: S486-94.

  50. Boris L, Steinkes JW. Cytokines and chemokines. J Allergy Clin Immunol. 2003; 111: S460-75.

  51. Rosenwasser LJ. New immunopharmacologic approaches to asthma: Role of cytokine antagonism. J Allergy Clin Immunol. 2000; 105: S586-92.

  52. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: An update. Pharmacol Rev. 1998; 50: 515-96.

  53. Holgate ST, Davies DE, Lacke PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol. 2000; 105: 193-204.

  54. Joos GF. The role of neuroeffector mechanisms in the pathogenesis of asthma. Curr Allergy Asthma Reports. 2001; 1: 134-43.

  55. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol. 2002; 109: 189-94.

  56. Reed C. The natural history of asthma. J Allergy Clin Immunol. 2006; 118: 543-8.

  57. Taussing L, Wright A, Holberg C, Jalonen M, Martinez F. Tucson Children’s Respiratory Study: 1980 to present. J Allergy Clin Immunol. 2003; 111: 661-75.

  58. Martínez F, Godfrey S. Epidemiology of wheezing in infants and preschool children. En: Martínez F, Godfrey S, Dunitz M, editores. Wheezing disorders in the preschool child. New York: Tylosr and Francis Group; 2003. p. 1-19.

  59. Castro-Rodriguez JA, Wright AL, Taussig LM. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000; 162: 1403-6.

  60. De Marco R, Pattaro C, Locatelli F, Svanes C, ECRHS Study Group. Influence of early life exposures on incidence and remission of asthma throughout life. J Allergy Clin Immunol. 2004; 113: 845-52.

  61. ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double blind, randomized, placebo controlled trial: first results of ETAC. Early treatment of atopic child. Pediatr Allergy Immunol. 1999; 9: 116.

  62. American Lung Association Medical Section: Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995; 152: 1107-14.

  63. American Thoracic Society/European Respiratory Society: Respiratory function measurements in infants: measurement conditions. Am J Respir Crit Care Med. 1995; 152: 1107.

  64. Godfrey S, Springer C, Bar-Yishay E. Cut-off points defining normal and asthmatic bronchial reactivity to exercise and inhalation challenges in children and young adults. Eur Respir J. 1999; 14: 659.

  65. Lemanske RF Jr, Busse WW. Asthma. J Allergy Clin Immunol. 2003; 111: S502-19.

  66. National Heart, Blood and Lung Institute Expert Panel Report 2. Guidelines for the diagnosis and management of asthma: update on selected topics 2002. NIH publication No. 02-5074. 2002.

  67. Lau S, Illi S, Sommerfeld C, Niggermann B. Early exposure to house dust mite and cat allergens and development of allergy in childhood a cohort study. Multicentric Allergy Study Group. Lancet. 2000; 356: 1392-7.

  68. Arruda LK, Vailes LD, Ferriani VPL, Santos ABR. Cockroach allergens and asthma. J Allergy Clin Immunol. 2001; 107: 419-28.

  69. Wijnands LM, Deisz WDC, van Leusden FM. Marker antigens to asses exposure to moulds and their allergens. Aspergillus fumigatus. Allergy. 2000; 55: 65-8.

  70. Gotzsche PC, Johanssen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. Cochrane database Syst Rev. 2004; 4: 357-69.

  71. Conner WT, Dolovich MB, Frank RA. Reliable salbutamol administration from 6 to 36 month old children by means of a metered-dose inhaler and aerochamber with facemask. Pediatr Pulmonol. 1989; 6: 263-71.

  72. Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol. 1989; 84: 891-8.

  73. Beakes DE. The use of anticholinergics in asthma. J Asthma. 1997; 34: 357-68.

  74. Szefl SJ. Glucocorticoid therapy for asthma: clinical pharmacology. J Allergy Clin Immunol. 1991; 88: 147-56.

  75. Bazzy-Asaad A. Departamento de Medicina Respiratoria Pediátrica, Universidad de Medicina Yale, Connecticut, EUA. Curren Opin Pediatr. 2001; 13: 523-7.

  76. Bisgaard H, Allen D, Milanowski J. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics. 2004; 113: 87-95.

  77. Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children. Am J Respir Crit Care Med.1999; 160: 126-31.

  78. Berger W. Ciclesonida: un novedoso corticosteroide inhalatorio para el tratamiento del asma persistente-perfil farmacológico y clínico. Therapy. 2005; 2: 167-78.

  79. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma: report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis.1990; 148: 1-26.

  80. Simons FE, Persaud MP, Gallespie CA, Cheang M, Shuckett EP. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet. 1993; 324: 776-8.

  81. Turpeinen M, Sorva R, Juntunen-Backman K. Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide. J Allergy Clin Immunol. 1991; 88: 384-9.

  82. Pawles R, Pedersen S, Busse W, Tan C, Chew YZ. Early intervention with budesonide in mild persistent asthma: A randomized, double–blind trial. Lancet. 2003; 361: 1071-6.

  83. Price J, Russell G, Hindmarsh P, Weller P. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol. 1997; 24: 78-186.

  84. Silverstein M, Yunginger J, Reed C, Petterson T. Attained adult height after childhood asthma: Effect of glucocorticoid therapy. J Allergy Clin Immunol. 1997; 99: 466-74.

  85. Agertoft L, Pedersen S. Effect of long term-treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000; 343: 1064-9.

  86. Pedersen S. State of the art. Do inhaled corticosteroid inhibit growth in children? Am J Respir Crit Care Med. 2001; 164: 521-35.

  87. Sim D, Griffiths A, Armstrong D, Clarke C. Adrenal suppression from high dose inhaled fluticasone in children with asthma. Eur Respir J. 2003; 21: 633-6.

  88. Milinarsky A, Fischer S, Giadrosich V, Lezana S, Torres MA. Efecto de dosis altas de budesonida y función suprarrenal de niños asmáticos severos. Rev Med Chile. 2006; 134: 60-4.

  89. Patel L, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child. 2001; 85: 330-4.

  90. Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving longterm treatment with inhaled budesonide. Am J Respir Crit Care Med. 1998; 157: 178-83.

  91. Griffiths A, Sim D, Strauss B, Rodda C. Effect of high-dose fluticasone propionate on bone density and metabolism in children with asthma. Pediatr Pulmonol. 2004; 37: 116-21.

  92. Hubbard R, Smith C, Smeeth L, Harrison T, Tattersfield A. Inhaled corticosteroids and hip fracture. A population-based case-control study. Am J Respir Crit Care Med. 2002; 166: 1563-6.

  93. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med. 2004; 169: 83-8.

  94. Gelfand EW, Georgitis JW, Noonan M, Ruff ME. Once daily ciclesonide in children: efficacy and safety in asthma. J Pediatr. 2006; 148: 377-83.

  95. Tasche MJ, Uijen JH, Bernsen RM. Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review. Thorax. 2000; 55: 913-20.

  96. Bisgaard H, Zielen S, Garcia-Garcia ML. Montelukast reduces asthma exacerbations in 2 to 5 year old children with intermittent asthma. Am J Respir Crit Care Med. 2005; 171: 315-22.

  97. Phipatanakul W, Greene C, Downes SJ. Montelukast improves asthma control is asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003; 91: 49.

  98. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003: CD001186.



>Revistas >Boletín Médico del Hospital Infantil de México >Año2009, No. 1
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019